FDA to quickly review Roche’s chemo-free lung cancer regimenRoche’s challenge to Merck & Co’s immunotherapy Keytruda in first line lung cancer has gathered momentum after the Share XFDA to quickly review Roche’s chemo-free lung cancer regimenhttps://pharmaphorum.com/news/roche-closing-in-on-chemo-free-first-line-nsclc-regimen/
Roche files Tecentriq, Avastin combo as a liver cancer therapyRoche has filed for approval of a two-drug combination of its Tecentriq and Avastin drugs in previously-untreated hepatocellular Share XRoche files Tecentriq, Avastin combo as a liver cancer therapyhttps://pharmaphorum.com/news/roche-files-tecentriq-avastin-combo-as-a-liver-cancer-therapy/
Roche steps up Merck challenge with first-line NSCLC approval in USRoche has scored another FDA approval for Tecentriq alongside chemotherapy for previously-untreated, non-squamous non-small cell lung cancer (NSCLC), Share XRoche steps up Merck challenge with first-line NSCLC approval in UShttps://pharmaphorum.com/news/roche-continues-merck-challenge-with-first-line-nsclc-approval-in-us/
Tecentriq beats rivals to EU breast cancer marketRoche has claimed approval in Europe for Tecentriq as a therapy for hard-to-treat triple-negative breast cancer (TNBC), ahead Share XTecentriq beats rivals to EU breast cancer markethttps://pharmaphorum.com/news/tecentriq-beats-rivals-to-eu-breast-cancer-market/
Roche scores with Tecentriq combo in first-line bladder cancerRoche’s Tecentriq has become the first checkpoint inhibitor to show a benefit in previously-untreated patients with bladder cancer Share XRoche scores with Tecentriq combo in first-line bladder cancerhttps://pharmaphorum.com/news/roche-scores-with-tecentriq-combo-in-first-line-bladder-cancer/
Roche raises 2019 outlook, shrugging off biosimilar threatNew product sales helped Roche to a healthy 9% increase in sales in the first half of the Share XRoche raises 2019 outlook, shrugging off biosimilar threathttps://pharmaphorum.com/news/roche-raises-2019-outlook-shrugging-off-biosimilar-threat/
Roche closes on EU approval for Tecentriq in breast cancerRoche is heading for EU approval of Tecentriq as first-line therapy for triple-negative breast cancer (TNBC), ahead of Share XRoche closes on EU approval for Tecentriq in breast cancerhttps://pharmaphorum.com/news/roche-closes-on-eu-approval-for-tecentriq-in-breast-cancer/
Roche’s Tecentriq gains new US lung cancer indicationRoche’s Tecentriq (atezolizumab) cancer immunotherapy has gained a new indication in the US, after the FDA granted it Share XRoche’s Tecentriq gains new US lung cancer indicationhttps://pharmaphorum.com/news/roches-tecentriq-gains-new-us-lung-cancer-indication/
Roche gets first checkpoint inhibitor OK in breast cancerRoche’s Tecentriq was the third PD-1/PD-L1 inhibitor to reach the market but is the first in class to Share XRoche gets first checkpoint inhibitor OK in breast cancerhttps://pharmaphorum.com/news/roche-gets-first-checkpoint-inhibitor-ok-in-breast-cancer/
